Advances in the treatment of giant cell arteritis

Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another extracranial or large vessel phenotype as the two more characteristic patterns. Permanent visual loss is the main short-...

Full description

Bibliographic Details
Authors: Castañeda Sanz, Santos, Prieto Peña, Diana, Vicente Rabaneda, Esther F., Triguero Martínez, Ana, Roy-Vallejo, Emilia, Atienza-Mateo, Belén, Blanco, Ricardo, Gonzalez-Gay, Miguel A.
Format: article
Publication Date:2022
Country:España
Institution:Universidad Autónoma de Madrid
Repository:Biblos-e Archivo. Repositorio Institucional de la UAM
Language:English
OAI Identifier:oai:repositorio.uam.es:10486/712709
Online Access:http://hdl.handle.net/10486/712709
https://dx.doi.org/10.3390/jcm11061588
Access Level:Open access
Keyword:giant cell arteritis
temporal arteritis
glucocorticoids
DMARD
methotrexate
tocilizumab
abatacept
ustekinumab
jakinibs
mavrilimumab
Medicina
id ES_5ba8bb304331bcbfff70c1f8b9be0bdf
oai_identifier_str oai:repositorio.uam.es:10486/712709
network_acronym_str ES
network_name_str España
repository_id_str
spelling Advances in the treatment of giant cell arteritisJournal of Clinical MedicineCastañeda Sanz, SantosPrieto Peña, DianaVicente Rabaneda, Esther F.Triguero Martínez, AnaRoy-Vallejo, EmiliaAtienza-Mateo, BelénBlanco, RicardoGonzalez-Gay, Miguel A.giant cell arteritistemporal arteritisglucocorticoidsDMARDmethotrexatetocilizumababataceptustekinumabjakinibsmavrilimumabMedicinaGiant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another extracranial or large vessel phenotype as the two more characteristic patterns. Permanent visual loss is the main short-term complication. Glucocorticoids (GC) remain the cornerstone of treatment. However, the percentage of relapses with GC alone is high, and the rate of adverse events affects more than 80% of patients, so it is necessary to have alternative therapeutic options, especially in patients with worse prognostic factors or high comorbidity. MTX is the only DMARD that has shown to reduce the cumulative dose of GC, while tocilizumab is the first biologic agent approved due to its ability to decrease the relapse rate and lower the cumulative GC doses. However, apart from the IL-6 pathway, there are other pro-inflammatory cytokines and growth factors involved in the typical intima hyperplasia and vascular remodeling of GCA. Among them, the more promising targets in GCA treatment are the IL12/IL23 axis antagonists, IL17 inhibitors, modulators of T lymphocytes, and inhibitors of either the JAK/STAT pathway, the granulocyte-macrophage colony-stimulating factor, or the endothelin, all of which are updated in this reviewThis line of research on vasculitis has been partially supported by FOREUM (Program Foundation for Research in Rheumatology) to the “START Project”, granted to Nicolò Pipitone (Reggio Emilia, Italy), in which SC and MAG-G are the main Spanish researchers (Spanish project number: NPI-TOC-2019-01). Moreover, this line of research has also been supported in part by RETICS Programs, RD08/0075 (RIER), RD12/0009/0013 and RD16/0012 from “Instituto de Salud Carlos III” (ISCIII) (Spain). However, this study did not receive any specific grant from funding agencies in the commercial or not-for-profit sectorsMDPIDepartamento de MedicinaFacultad de Medicina20222022-03-13research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/712709https://dx.doi.org/10.3390/jcm11061588reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7127092026-06-23T12:46:27Z
dc.title.none.fl_str_mv Advances in the treatment of giant cell arteritis
Journal of Clinical Medicine
title Advances in the treatment of giant cell arteritis
spellingShingle Advances in the treatment of giant cell arteritis
Castañeda Sanz, Santos
giant cell arteritis
temporal arteritis
glucocorticoids
DMARD
methotrexate
tocilizumab
abatacept
ustekinumab
jakinibs
mavrilimumab
Medicina
title_short Advances in the treatment of giant cell arteritis
title_full Advances in the treatment of giant cell arteritis
title_fullStr Advances in the treatment of giant cell arteritis
title_full_unstemmed Advances in the treatment of giant cell arteritis
title_sort Advances in the treatment of giant cell arteritis
dc.creator.none.fl_str_mv Castañeda Sanz, Santos
Prieto Peña, Diana
Vicente Rabaneda, Esther F.
Triguero Martínez, Ana
Roy-Vallejo, Emilia
Atienza-Mateo, Belén
Blanco, Ricardo
Gonzalez-Gay, Miguel A.
author Castañeda Sanz, Santos
author_facet Castañeda Sanz, Santos
Prieto Peña, Diana
Vicente Rabaneda, Esther F.
Triguero Martínez, Ana
Roy-Vallejo, Emilia
Atienza-Mateo, Belén
Blanco, Ricardo
Gonzalez-Gay, Miguel A.
author_role author
author2 Prieto Peña, Diana
Vicente Rabaneda, Esther F.
Triguero Martínez, Ana
Roy-Vallejo, Emilia
Atienza-Mateo, Belén
Blanco, Ricardo
Gonzalez-Gay, Miguel A.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv giant cell arteritis
temporal arteritis
glucocorticoids
DMARD
methotrexate
tocilizumab
abatacept
ustekinumab
jakinibs
mavrilimumab
Medicina
topic giant cell arteritis
temporal arteritis
glucocorticoids
DMARD
methotrexate
tocilizumab
abatacept
ustekinumab
jakinibs
mavrilimumab
Medicina
description Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another extracranial or large vessel phenotype as the two more characteristic patterns. Permanent visual loss is the main short-term complication. Glucocorticoids (GC) remain the cornerstone of treatment. However, the percentage of relapses with GC alone is high, and the rate of adverse events affects more than 80% of patients, so it is necessary to have alternative therapeutic options, especially in patients with worse prognostic factors or high comorbidity. MTX is the only DMARD that has shown to reduce the cumulative dose of GC, while tocilizumab is the first biologic agent approved due to its ability to decrease the relapse rate and lower the cumulative GC doses. However, apart from the IL-6 pathway, there are other pro-inflammatory cytokines and growth factors involved in the typical intima hyperplasia and vascular remodeling of GCA. Among them, the more promising targets in GCA treatment are the IL12/IL23 axis antagonists, IL17 inhibitors, modulators of T lymphocytes, and inhibitors of either the JAK/STAT pathway, the granulocyte-macrophage colony-stimulating factor, or the endothelin, all of which are updated in this review
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-03-13
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/712709
https://dx.doi.org/10.3390/jcm11061588
url http://hdl.handle.net/10486/712709
https://dx.doi.org/10.3390/jcm11061588
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408818356551680
score 15.301603

Similar Items